1 / 12

Stroke Council Professional Education Committee

EXPANSION OF THE TIME WINDOW FOR TREATMENT OF ACUTE ISCHEMIC STROKE WITH INTRAVENOUS TISSUE PLASMINOGEN ACTIVATOR An Advisory Statement from the Stroke Council, American Heart Association and American Stroke Association

vladimir-valenzuela
Download Presentation

Stroke Council Professional Education Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EXPANSION OF THE TIME WINDOW FOR TREATMENT OF ACUTE ISCHEMIC STROKE WITH INTRAVENOUS TISSUE PLASMINOGEN ACTIVATOR An Advisory Statement from the Stroke Council, American Heart Association and American Stroke Association Gregory J. del Zoppo, MD, MS, FAHA; Jeffrey L. Saver, MD, FAHA; Edward C. Jauch, M.D, MS, FAHA; Harold P. Adams, Jr., MD, FAHA This science advisory reflects a consensus of expert opinion following thorough literature review that consisted of a look at clinical trials and other evidence related to the management of acute ischemic stroke.

  2. Stroke Council Professional Education Committee Slide presentation for developed by: Opeolu Adeoye MD Dawn Kleindorfer MD • Key words included in the paper: ischemic stroke; tissue plasminogen activator; cerebrovascular disorders; hemorrhage; stroke

  3. Applying classification of recommendations and levels of evidence

  4. Current Management • rt-PA is recommended for treatment of ischemic stroke in selected patients • However, rt-PA is only administered to less than 3% of ischemic stroke patients • Delay in presentation contributes significantly to underutilization of rt-PA for stroke • Extending time window for rt-PA administration beyond the current recommended 3 hrs might be beneficial. • The European Cooperative Acute Stroke Study (ECASS 3), investigated rt-PA (alteplase) treatment in the 3.0 - 4.5 hour window

  5. ECASS - 3 DESIGN AND METHODS • Multicenter, prospective, placebo-controlled RCT • Usual criteria for rt-PA eligibility within 3 hrs, exclusion criteria included: • older than 80 years; baseline NIH Stroke Scale score >25; on oral anticoagulants; combo of a previous stroke & DM • rt-PA (n = 418) or placebo (n = 403) given at 3.0 - 4.5 hrs from stroke symptom onset • Dose = 0.9 mg/kg (max 90 mg); 10% as initial bolus & remainder infused over 1 hr. • Primary outcome: modified Rankin Scale Score 0-1 (minimal or no disability) at 90 days after Tx.

  6. ECASS - 3 RESULTS Primary Outcome: • mRS 0-1: rt-PA (52.4%) vs placebo (45.2%) (OR 1.34, 95% CI = 1.02-1.76; p = 0.04) Secondary Outcome: Global Favorable Outcome (mRS of 0-1, Barthel Index score >95, an NIHSS score of 0-1& Glascow Outcome Score of 1) • ECASS – 3 = OR 1.28, 95% CI = 1.00-1.65) vs NINDS pool pts (enrolled 0-3hrs) = OR1.9, 95% CI 1.2-2.9 (Overlap in CI limits conclusions about these observations)

  7. ECASS - 3 RESULTS • Symptomatic ICH (ECASS-3 definition) occurred in rt-PA n = 10 (2.4%) vs placebo n = 1 (0.2%) (OR 9.85, 95% CI 1.26-77.32, p = 0.008) • Symptomatic ICH (NINDS study definition) occurred in rt-PA n = 33 (7.9%) vs placebo n = 14 (3.5%) (OR 2.38, 95% CI = 1.25-4.52, p = 0.006) • Increased incidence of symptomatic ICH is consistent with the experience with rt-PA in other clinical trials with rt-PA • Mortality in the two treatment groups did not differ significantly, although it was nominally higher among the subjects treated with placebo (7.7% vs. 8.4%, p=0.68) Information from the Expansion of the Time Window for Treatment of Acute Ischemic Stroke with IV TPA – Science Advisory

  8. ECASS – 3 CONCLUSIONS • The ECASS-3 trial is an important advance in treatment of acute ischemic stroke • The results provide level B evidence that intravenous rt-PA can be given safely to carefully selected patients 3.0-4.5 hours after stroke • These results are consistent with previous reports and confirmation of the ECASS-3 outcome in encouraged

  9. Recommendations • Patients who are eligible for treatment with rt-PA within 3 hours of onset of stroke should be treated as recommended in the 2007 guidelines • Delays in evaluation and initiation of therapy should be avoided because the opportunity for improvement is greater with earlier treatment

  10. Recommendations • rt-PA should be administered to eligible pts within 3.0-4.5 hours after stroke (Class I Recommendation, LOE B) • Eligibility criteria in this time period are similar to those for persons treated at earlier time periods with the following additional exclusion criteria: • Age > 80 years; Oral anticoagulant use with INR ≤ 1.7*; baseline NIH Stroke Scale score > 25; a history of stroke and diabetes (*For the 3.0 – 4.5 hr window all pts receiving oral anticoagulant are excluded whatever their INR). • The efficacy of IV rt-PA within 3.0 – 4.5 hours after stroke in pts with these exclusion criteria is not well-established & requires further study. (Class IIb Recommendation, LOE C)

  11. Summary • rt-PA may be safely administered to ischemic stroke pts meeting strict inclusion & exclusion criteria in the 3.0-4.5 hr time window • Ancillary care for pts receiving rt-PA at 3.0-4.5 hrs after ischemic stroke should be similar to that included in the 2007 AHA Stroke Guidelines

More Related